CPA
TNYA icon

Capital Performance Advisors’s Tenaya Therapeutics TNYA Stock Holding History

Capital Performance Advisors’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12
Closed -$23 – 2463
2024
Q3 		$23 Buy
+12
New +$34 ﹤0.01% 2848

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Capital Performance Advisors's TNYA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Tenaya Therapeutics (TNYA) in Q4 2024, closing a stake of 12 shares — an estimated $23 sold.

Capital Performance Advisors first reported a position in TNYA in Q3 2024 and held it in 1 quarter. The position peaked at $23 in Q3 2024. 88 funds tracked by Wall St. Rank hold TNYA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Tenaya Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 12 Tenaya Therapeutics shares in Q4 2024, an estimated $23.
  • Capital Performance Advisors first reported a position in Tenaya Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Tenaya Therapeutics position peaked at $23 in Q3 2024.
  • 88 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.